Vericel Corp (VCEL) Insider Dominick Colangelo Sells 50,000 Shares

Vericel Corp (NASDAQ:VCEL) insider Dominick Colangelo sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 6th. The stock was sold at an average price of $15.39, for a total transaction of $769,500.00. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Dominick Colangelo also recently made the following trade(s):

  • On Thursday, October 4th, Dominick Colangelo sold 75,000 shares of Vericel stock. The shares were sold at an average price of $15.02, for a total transaction of $1,126,500.00.

Shares of Vericel stock opened at $16.11 on Friday. The firm has a market capitalization of $711.40 million, a PE ratio of -32.22 and a beta of 3.36. Vericel Corp has a 12 month low of $3.63 and a 12 month high of $17.51. The company has a debt-to-equity ratio of 0.16, a quick ratio of 7.48 and a current ratio of 7.72.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.09. Vericel had a negative net margin of 15.80% and a negative return on equity of 22.23%. The firm had revenue of $22.50 million for the quarter, compared to analyst estimates of $18.14 million. Vericel’s revenue for the quarter was up 57.3% on a year-over-year basis. As a group, equities research analysts expect that Vericel Corp will post -0.27 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of the stock. American International Group Inc. grew its position in Vericel by 18.6% in the 3rd quarter. American International Group Inc. now owns 28,505 shares of the biotechnology company’s stock valued at $403,000 after buying an additional 4,474 shares during the last quarter. Bank of New York Mellon Corp grew its position in Vericel by 4.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 132,888 shares of the biotechnology company’s stock valued at $1,289,000 after buying an additional 5,854 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. grew its position in Vericel by 60.0% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 16,005 shares of the biotechnology company’s stock valued at $159,000 after buying an additional 6,000 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. grew its position in Vericel by 10.7% in the 3rd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 68,170 shares of the biotechnology company’s stock valued at $965,000 after buying an additional 6,580 shares during the last quarter. Finally, Perkins Capital Management Inc. grew its position in Vericel by 1.3% in the 2nd quarter. Perkins Capital Management Inc. now owns 552,100 shares of the biotechnology company’s stock valued at $5,355,000 after buying an additional 7,150 shares during the last quarter. Hedge funds and other institutional investors own 76.57% of the company’s stock.

A number of equities analysts have recently commented on VCEL shares. BidaskClub cut shares of Vericel from a “hold” rating to a “sell” rating in a report on Tuesday, October 23rd. LADENBURG THALM/SH SH raised shares of Vericel from a “neutral” rating to a “buy” rating in a report on Monday, July 16th. BTIG Research lifted their target price on shares of Vericel from $17.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Needham & Company LLC cut their target price on shares of Vericel from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Wednesday, August 8th. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $16.75.

TRADEMARK VIOLATION NOTICE: “Vericel Corp (VCEL) Insider Dominick Colangelo Sells 50,000 Shares” was first posted by WKRB News and is the property of of WKRB News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.wkrb13.com/2018/11/10/vericel-corp-vcel-insider-dominick-colangelo-sells-50000-shares.html.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure.

Recommended Story: Diversification For Individual Investors

Insider Buying and Selling by Quarter for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply